Key result
Glycoprotein IIb-IIIa receptor antagonists demonstrate benefits over conventional antiplatelet therapy in patients undergoing percutaneous coronary angioplasty and with acute coronary syndromes.
Why the study?
Do glycoprotein IIb-IIIa receptor antagonists improve outcomes in patients undergoing percutaneous coronary angioplasty and with acute coronary syndromes compared to conventional antiplatelet therapy?
Population
Patients undergoing percutaneous coronary angioplasty, patients with acute coronary syndromes, and patients…
Comparison
Glycoprotein IIb-IIIa receptor antagonists vs Conventional antiplatelet therapy
Design
Review
Authors
Loading...
Supports adjunctive GP IIb/IIIa use in PCI and ACS; extends prior data but warrants reevaluation with modern regimens.
Do glycoprotein IIb-IIIa receptor antagonists improve outcomes in patients undergoing percutaneous coronary angioplasty and with acute coronary syndromes compared to conventional antiplatelet therapy?
Glycoprotein IIb-IIIa receptor antagonists provide clinical benefits over conventional antiplatelet therapy in patients undergoing percutaneous coronary angioplasty and those with acute coronary syndromes.
Winkelmann et al. (1997) conducted a review in Acute coronary syndromes and percutaneous coronary angioplasty. Glycoprotein IIb-IIIa receptor antagonists vs. Conventional antiplatelet therapy was evaluated. Glycoprotein IIb-IIIa receptor antagonists demonstrate benefits over conventional antiplatelet therapy in patients undergoing percutaneous coronary angioplasty and with acute coronary syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: